nodes	percent_of_prediction	percent_of_DWPC	metapath
Nefazodone—CYP2D6—breast cancer	0.112	0.389	CbGaD
Nefazodone—CYP3A4—breast cancer	0.0961	0.333	CbGaD
Nefazodone—ABCB1—breast cancer	0.08	0.278	CbGaD
Nefazodone—CYP3A5—Lapatinib—breast cancer	0.0235	0.055	CbGbCtD
Nefazodone—ABCB1—Toremifene—breast cancer	0.021	0.049	CbGbCtD
Nefazodone—CYP3A4—Exemestane—breast cancer	0.0181	0.0424	CbGbCtD
Nefazodone—CYP2D6—Idarubicin—breast cancer	0.0164	0.0383	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Tamoxifen—breast cancer	0.0157	0.0367	CbGbCtD
Nefazodone—CYP3A7—Tamoxifen—breast cancer	0.0157	0.0367	CbGbCtD
Nefazodone—CYP3A4—Letrozole—breast cancer	0.0154	0.036	CbGbCtD
Nefazodone—ABCB1—Lapatinib—breast cancer	0.0153	0.0358	CbGbCtD
Nefazodone—CYP3A4—Anastrozole—breast cancer	0.0137	0.0321	CbGbCtD
Nefazodone—CYP3A4—Toremifene—breast cancer	0.0126	0.0294	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Paclitaxel—breast cancer	0.0122	0.0286	CbGbCtD
Nefazodone—CYP3A7—Paclitaxel—breast cancer	0.0122	0.0286	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Irinotecan—breast cancer	0.0121	0.0282	CbGbCtD
Nefazodone—CYP3A7—Irinotecan—breast cancer	0.0121	0.0282	CbGbCtD
Nefazodone—CYP3A5—Tamoxifen—breast cancer	0.0118	0.0275	CbGbCtD
Nefazodone—CYP3A4—Fulvestrant—breast cancer	0.0117	0.0273	CbGbCtD
Nefazodone—CYP3A4—Thiotepa—breast cancer	0.0104	0.0243	CbGbCtD
Nefazodone—CYP3A4—Ixabepilone—breast cancer	0.00953	0.0223	CbGbCtD
Nefazodone—CYP3A4—Lapatinib—breast cancer	0.00917	0.0214	CbGbCtD
Nefazodone—CYP3A5—Paclitaxel—breast cancer	0.00917	0.0214	CbGbCtD
Nefazodone—CYP3A5—Irinotecan—breast cancer	0.00904	0.0211	CbGbCtD
Nefazodone—CYP3A7-CYP3A51P—Docetaxel—breast cancer	0.00884	0.0206	CbGbCtD
Nefazodone—CYP3A7—Docetaxel—breast cancer	0.00884	0.0206	CbGbCtD
Nefazodone—ABCB1—Vinorelbine—breast cancer	0.00849	0.0198	CbGbCtD
Nefazodone—CYP2D6—Vinorelbine—breast cancer	0.008	0.0187	CbGbCtD
Nefazodone—ABCB1—Tamoxifen—breast cancer	0.00767	0.0179	CbGbCtD
Nefazodone—ABCB1—Mitoxantrone—breast cancer	0.00748	0.0175	CbGbCtD
Nefazodone—CYP2D6—Tamoxifen—breast cancer	0.00722	0.0169	CbGbCtD
Nefazodone—CYP3A4—Raloxifene—breast cancer	0.00695	0.0162	CbGbCtD
Nefazodone—CYP3A5—Docetaxel—breast cancer	0.00663	0.0155	CbGbCtD
Nefazodone—ABCB1—Gemcitabine—breast cancer	0.0066	0.0154	CbGbCtD
Nefazodone—ABCB1—Paclitaxel—breast cancer	0.00597	0.0139	CbGbCtD
Nefazodone—ABCB1—Irinotecan—breast cancer	0.00589	0.0138	CbGbCtD
Nefazodone—ABCB1—Vinblastine—breast cancer	0.00523	0.0122	CbGbCtD
Nefazodone—CYP3A4—Vinorelbine—breast cancer	0.00509	0.0119	CbGbCtD
Nefazodone—CYP2D6—Vinblastine—breast cancer	0.00493	0.0115	CbGbCtD
Nefazodone—CYP3A4—Tamoxifen—breast cancer	0.00459	0.0107	CbGbCtD
Nefazodone—CYP3A4—Mitoxantrone—breast cancer	0.00448	0.0105	CbGbCtD
Nefazodone—ABCB1—Docetaxel—breast cancer	0.00431	0.0101	CbGbCtD
Nefazodone—CYP3A4—Paclitaxel—breast cancer	0.00357	0.00835	CbGbCtD
Nefazodone—CYP3A4—Irinotecan—breast cancer	0.00353	0.00824	CbGbCtD
Nefazodone—ABCB1—Doxorubicin—breast cancer	0.00322	0.00751	CbGbCtD
Nefazodone—CYP3A4—Vinblastine—breast cancer	0.00314	0.00733	CbGbCtD
Nefazodone—ABCB1—Methotrexate—breast cancer	0.00311	0.00728	CbGbCtD
Nefazodone—CYP2D6—Doxorubicin—breast cancer	0.00303	0.00708	CbGbCtD
Nefazodone—CYP3A4—Docetaxel—breast cancer	0.00258	0.00604	CbGbCtD
Nefazodone—CYP3A4—Doxorubicin—breast cancer	0.00193	0.0045	CbGbCtD
Nefazodone—Trifluoperazine—S100A4—breast cancer	0.000946	0.343	CrCbGaD
Nefazodone—Hydroxyzine—CYP2D6—breast cancer	0.000196	0.0711	CrCbGaD
Nefazodone—Domperidone—CYP2D6—breast cancer	0.000126	0.0458	CrCbGaD
Nefazodone—Domperidone—CYP3A4—breast cancer	0.000108	0.0393	CrCbGaD
Nefazodone—Zuclopenthixol—CYP2D6—breast cancer	0.000106	0.0383	CrCbGaD
Nefazodone—Aripiprazole—CYP2D6—breast cancer	9.75e-05	0.0354	CrCbGaD
Nefazodone—Trazodone—CYP2D6—breast cancer	9.71e-05	0.0352	CrCbGaD
Nefazodone—Domperidone—ABCB1—breast cancer	9.02e-05	0.0327	CrCbGaD
Nefazodone—Prochlorperazine—CYP2D6—breast cancer	8.69e-05	0.0315	CrCbGaD
Nefazodone—Aripiprazole—CYP3A4—breast cancer	8.36e-05	0.0304	CrCbGaD
Nefazodone—Trazodone—CYP3A4—breast cancer	8.33e-05	0.0302	CrCbGaD
Nefazodone—Fluphenazine—CYP2D6—breast cancer	7.86e-05	0.0285	CrCbGaD
Nefazodone—Prochlorperazine—CYP3A4—breast cancer	7.46e-05	0.0271	CrCbGaD
Nefazodone—Aripiprazole—ABCB1—breast cancer	6.96e-05	0.0253	CrCbGaD
Nefazodone—Trazodone—ABCB1—breast cancer	6.93e-05	0.0252	CrCbGaD
Nefazodone—Thioproperazine—ALB—breast cancer	6.92e-05	0.0251	CrCbGaD
Nefazodone—Perphenazine—CYP2D6—breast cancer	6.22e-05	0.0226	CrCbGaD
Nefazodone—Quetiapine—CYP2D6—breast cancer	6.1e-05	0.0221	CrCbGaD
Nefazodone—Fluphenazine—ABCB1—breast cancer	5.61e-05	0.0204	CrCbGaD
Nefazodone—Perphenazine—CYP3A4—breast cancer	5.33e-05	0.0194	CrCbGaD
Nefazodone—Quetiapine—CYP3A4—breast cancer	5.23e-05	0.019	CrCbGaD
Nefazodone—Trifluoperazine—ABCB1—breast cancer	4.49e-05	0.0163	CrCbGaD
Nefazodone—Quetiapine—ABCB1—breast cancer	4.35e-05	0.0158	CrCbGaD
Nefazodone—Musculoskeletal discomfort—Docetaxel—breast cancer	3.47e-05	0.000174	CcSEcCtD
Nefazodone—Chills—Methotrexate—breast cancer	3.47e-05	0.000174	CcSEcCtD
Nefazodone—Headache—Mitoxantrone—breast cancer	3.45e-05	0.000173	CcSEcCtD
Nefazodone—Headache—Irinotecan—breast cancer	3.45e-05	0.000173	CcSEcCtD
Nefazodone—Hypotension—Capecitabine—breast cancer	3.44e-05	0.000173	CcSEcCtD
Nefazodone—Insomnia—Docetaxel—breast cancer	3.44e-05	0.000173	CcSEcCtD
Nefazodone—Paraesthesia—Docetaxel—breast cancer	3.42e-05	0.000172	CcSEcCtD
Nefazodone—Erythema multiforme—Epirubicin—breast cancer	3.42e-05	0.000172	CcSEcCtD
Nefazodone—Alopecia—Methotrexate—breast cancer	3.41e-05	0.000172	CcSEcCtD
Nefazodone—Vomiting—Gemcitabine—breast cancer	3.41e-05	0.000171	CcSEcCtD
Nefazodone—Bradycardia—Doxorubicin—breast cancer	3.4e-05	0.000171	CcSEcCtD
Nefazodone—Dyspnoea—Docetaxel—breast cancer	3.39e-05	0.000171	CcSEcCtD
Nefazodone—Somnolence—Docetaxel—breast cancer	3.38e-05	0.00017	CcSEcCtD
Nefazodone—Rash—Gemcitabine—breast cancer	3.38e-05	0.00017	CcSEcCtD
Nefazodone—Dermatitis—Gemcitabine—breast cancer	3.38e-05	0.00017	CcSEcCtD
Nefazodone—Tinnitus—Epirubicin—breast cancer	3.37e-05	0.000169	CcSEcCtD
Nefazodone—Haemoglobin—Doxorubicin—breast cancer	3.36e-05	0.000169	CcSEcCtD
Nefazodone—Headache—Gemcitabine—breast cancer	3.36e-05	0.000169	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Capecitabine—breast cancer	3.36e-05	0.000169	CcSEcCtD
Nefazodone—Flushing—Epirubicin—breast cancer	3.35e-05	0.000169	CcSEcCtD
Nefazodone—Vomiting—Fluorouracil—breast cancer	3.35e-05	0.000169	CcSEcCtD
Nefazodone—Rhinitis—Doxorubicin—breast cancer	3.35e-05	0.000168	CcSEcCtD
Nefazodone—Dyspepsia—Docetaxel—breast cancer	3.35e-05	0.000168	CcSEcCtD
Nefazodone—Hepatitis—Doxorubicin—breast cancer	3.34e-05	0.000168	CcSEcCtD
Nefazodone—Haemorrhage—Doxorubicin—breast cancer	3.34e-05	0.000168	CcSEcCtD
Nefazodone—Insomnia—Capecitabine—breast cancer	3.33e-05	0.000168	CcSEcCtD
Nefazodone—Hypoaesthesia—Doxorubicin—breast cancer	3.33e-05	0.000167	CcSEcCtD
Nefazodone—Rash—Fluorouracil—breast cancer	3.33e-05	0.000167	CcSEcCtD
Nefazodone—Dermatitis—Fluorouracil—breast cancer	3.32e-05	0.000167	CcSEcCtD
Nefazodone—Pharyngitis—Doxorubicin—breast cancer	3.32e-05	0.000167	CcSEcCtD
Nefazodone—Paraesthesia—Capecitabine—breast cancer	3.31e-05	0.000166	CcSEcCtD
Nefazodone—Decreased appetite—Docetaxel—breast cancer	3.31e-05	0.000166	CcSEcCtD
Nefazodone—Hypersensitivity—Paclitaxel—breast cancer	3.31e-05	0.000166	CcSEcCtD
Nefazodone—Headache—Fluorouracil—breast cancer	3.3e-05	0.000166	CcSEcCtD
Nefazodone—Oedema peripheral—Doxorubicin—breast cancer	3.29e-05	0.000166	CcSEcCtD
Nefazodone—Dysgeusia—Methotrexate—breast cancer	3.29e-05	0.000165	CcSEcCtD
Nefazodone—Dyspnoea—Capecitabine—breast cancer	3.29e-05	0.000165	CcSEcCtD
Nefazodone—Nausea—Mitoxantrone—breast cancer	3.27e-05	0.000164	CcSEcCtD
Nefazodone—Nausea—Irinotecan—breast cancer	3.27e-05	0.000164	CcSEcCtD
Nefazodone—Constipation—Docetaxel—breast cancer	3.26e-05	0.000164	CcSEcCtD
Nefazodone—Pain—Docetaxel—breast cancer	3.26e-05	0.000164	CcSEcCtD
Nefazodone—Back pain—Methotrexate—breast cancer	3.25e-05	0.000163	CcSEcCtD
Nefazodone—Dyspepsia—Capecitabine—breast cancer	3.24e-05	0.000163	CcSEcCtD
Nefazodone—Chills—Epirubicin—breast cancer	3.24e-05	0.000163	CcSEcCtD
Nefazodone—Visual impairment—Doxorubicin—breast cancer	3.22e-05	0.000162	CcSEcCtD
Nefazodone—Asthenia—Paclitaxel—breast cancer	3.22e-05	0.000162	CcSEcCtD
Nefazodone—Decreased appetite—Capecitabine—breast cancer	3.2e-05	0.000161	CcSEcCtD
Nefazodone—Alopecia—Epirubicin—breast cancer	3.19e-05	0.00016	CcSEcCtD
Nefazodone—Nausea—Gemcitabine—breast cancer	3.19e-05	0.00016	CcSEcCtD
Nefazodone—Pruritus—Paclitaxel—breast cancer	3.18e-05	0.00016	CcSEcCtD
Nefazodone—Vision blurred—Methotrexate—breast cancer	3.17e-05	0.000159	CcSEcCtD
Nefazodone—Erythema multiforme—Doxorubicin—breast cancer	3.16e-05	0.000159	CcSEcCtD
Nefazodone—Pain—Capecitabine—breast cancer	3.15e-05	0.000158	CcSEcCtD
Nefazodone—Constipation—Capecitabine—breast cancer	3.15e-05	0.000158	CcSEcCtD
Nefazodone—Feeling abnormal—Docetaxel—breast cancer	3.14e-05	0.000158	CcSEcCtD
Nefazodone—Nausea—Fluorouracil—breast cancer	3.13e-05	0.000157	CcSEcCtD
Nefazodone—Ill-defined disorder—Methotrexate—breast cancer	3.12e-05	0.000157	CcSEcCtD
Nefazodone—Tinnitus—Doxorubicin—breast cancer	3.12e-05	0.000157	CcSEcCtD
Nefazodone—Gastrointestinal pain—Docetaxel—breast cancer	3.11e-05	0.000156	CcSEcCtD
Nefazodone—Anaemia—Methotrexate—breast cancer	3.11e-05	0.000156	CcSEcCtD
Nefazodone—Flushing—Doxorubicin—breast cancer	3.1e-05	0.000156	CcSEcCtD
Nefazodone—Flatulence—Epirubicin—breast cancer	3.1e-05	0.000156	CcSEcCtD
Nefazodone—Dysgeusia—Epirubicin—breast cancer	3.08e-05	0.000155	CcSEcCtD
Nefazodone—Diarrhoea—Paclitaxel—breast cancer	3.07e-05	0.000154	CcSEcCtD
Nefazodone—Back pain—Epirubicin—breast cancer	3.04e-05	0.000153	CcSEcCtD
Nefazodone—Feeling abnormal—Capecitabine—breast cancer	3.04e-05	0.000153	CcSEcCtD
Nefazodone—Malaise—Methotrexate—breast cancer	3.03e-05	0.000152	CcSEcCtD
Nefazodone—Muscle spasms—Epirubicin—breast cancer	3.03e-05	0.000152	CcSEcCtD
Nefazodone—Vertigo—Methotrexate—breast cancer	3.02e-05	0.000152	CcSEcCtD
Nefazodone—Gastrointestinal pain—Capecitabine—breast cancer	3.01e-05	0.000151	CcSEcCtD
Nefazodone—Abdominal pain—Docetaxel—breast cancer	3.01e-05	0.000151	CcSEcCtD
Nefazodone—Body temperature increased—Docetaxel—breast cancer	3.01e-05	0.000151	CcSEcCtD
Nefazodone—Leukopenia—Methotrexate—breast cancer	3.01e-05	0.000151	CcSEcCtD
Nefazodone—Chills—Doxorubicin—breast cancer	3e-05	0.000151	CcSEcCtD
Nefazodone—Dizziness—Paclitaxel—breast cancer	2.97e-05	0.000149	CcSEcCtD
Nefazodone—Vision blurred—Epirubicin—breast cancer	2.97e-05	0.000149	CcSEcCtD
Nefazodone—Alopecia—Doxorubicin—breast cancer	2.96e-05	0.000149	CcSEcCtD
Nefazodone—Cough—Methotrexate—breast cancer	2.93e-05	0.000147	CcSEcCtD
Nefazodone—Urticaria—Capecitabine—breast cancer	2.93e-05	0.000147	CcSEcCtD
Nefazodone—Ill-defined disorder—Epirubicin—breast cancer	2.92e-05	0.000147	CcSEcCtD
Nefazodone—Abdominal pain—Capecitabine—breast cancer	2.91e-05	0.000146	CcSEcCtD
Nefazodone—Body temperature increased—Capecitabine—breast cancer	2.91e-05	0.000146	CcSEcCtD
Nefazodone—Convulsion—Methotrexate—breast cancer	2.91e-05	0.000146	CcSEcCtD
Nefazodone—Anaemia—Epirubicin—breast cancer	2.91e-05	0.000146	CcSEcCtD
Nefazodone—Agitation—Epirubicin—breast cancer	2.89e-05	0.000145	CcSEcCtD
Nefazodone—Flatulence—Doxorubicin—breast cancer	2.87e-05	0.000144	CcSEcCtD
Nefazodone—Myalgia—Methotrexate—breast cancer	2.86e-05	0.000144	CcSEcCtD
Nefazodone—Arthralgia—Methotrexate—breast cancer	2.86e-05	0.000144	CcSEcCtD
Nefazodone—Chest pain—Methotrexate—breast cancer	2.86e-05	0.000144	CcSEcCtD
Nefazodone—Vomiting—Paclitaxel—breast cancer	2.86e-05	0.000144	CcSEcCtD
Nefazodone—Dysgeusia—Doxorubicin—breast cancer	2.85e-05	0.000143	CcSEcCtD
Nefazodone—Malaise—Epirubicin—breast cancer	2.84e-05	0.000143	CcSEcCtD
Nefazodone—Rash—Paclitaxel—breast cancer	2.83e-05	0.000142	CcSEcCtD
Nefazodone—Dermatitis—Paclitaxel—breast cancer	2.83e-05	0.000142	CcSEcCtD
Nefazodone—Discomfort—Methotrexate—breast cancer	2.83e-05	0.000142	CcSEcCtD
Nefazodone—Vertigo—Epirubicin—breast cancer	2.83e-05	0.000142	CcSEcCtD
Nefazodone—Syncope—Epirubicin—breast cancer	2.82e-05	0.000142	CcSEcCtD
Nefazodone—Leukopenia—Epirubicin—breast cancer	2.82e-05	0.000142	CcSEcCtD
Nefazodone—Back pain—Doxorubicin—breast cancer	2.82e-05	0.000142	CcSEcCtD
Nefazodone—Headache—Paclitaxel—breast cancer	2.81e-05	0.000141	CcSEcCtD
Nefazodone—Hypersensitivity—Docetaxel—breast cancer	2.81e-05	0.000141	CcSEcCtD
Nefazodone—Muscle spasms—Doxorubicin—breast cancer	2.8e-05	0.000141	CcSEcCtD
Nefazodone—Palpitations—Epirubicin—breast cancer	2.78e-05	0.00014	CcSEcCtD
Nefazodone—Confusional state—Methotrexate—breast cancer	2.77e-05	0.000139	CcSEcCtD
Nefazodone—Loss of consciousness—Epirubicin—breast cancer	2.77e-05	0.000139	CcSEcCtD
Nefazodone—Cough—Epirubicin—breast cancer	2.75e-05	0.000138	CcSEcCtD
Nefazodone—Anaphylactic shock—Methotrexate—breast cancer	2.74e-05	0.000138	CcSEcCtD
Nefazodone—Vision blurred—Doxorubicin—breast cancer	2.74e-05	0.000138	CcSEcCtD
Nefazodone—Asthenia—Docetaxel—breast cancer	2.73e-05	0.000137	CcSEcCtD
Nefazodone—Convulsion—Epirubicin—breast cancer	2.73e-05	0.000137	CcSEcCtD
Nefazodone—Infection—Methotrexate—breast cancer	2.73e-05	0.000137	CcSEcCtD
Nefazodone—Hypertension—Epirubicin—breast cancer	2.72e-05	0.000137	CcSEcCtD
Nefazodone—Hypersensitivity—Capecitabine—breast cancer	2.72e-05	0.000136	CcSEcCtD
Nefazodone—Ill-defined disorder—Doxorubicin—breast cancer	2.7e-05	0.000136	CcSEcCtD
Nefazodone—Pruritus—Docetaxel—breast cancer	2.69e-05	0.000135	CcSEcCtD
Nefazodone—Anaemia—Doxorubicin—breast cancer	2.69e-05	0.000135	CcSEcCtD
Nefazodone—Thrombocytopenia—Methotrexate—breast cancer	2.69e-05	0.000135	CcSEcCtD
Nefazodone—Chest pain—Epirubicin—breast cancer	2.68e-05	0.000135	CcSEcCtD
Nefazodone—Myalgia—Epirubicin—breast cancer	2.68e-05	0.000135	CcSEcCtD
Nefazodone—Arthralgia—Epirubicin—breast cancer	2.68e-05	0.000135	CcSEcCtD
Nefazodone—Agitation—Doxorubicin—breast cancer	2.68e-05	0.000134	CcSEcCtD
Nefazodone—Anxiety—Epirubicin—breast cancer	2.67e-05	0.000134	CcSEcCtD
Nefazodone—Nausea—Paclitaxel—breast cancer	2.67e-05	0.000134	CcSEcCtD
Nefazodone—Hyperhidrosis—Methotrexate—breast cancer	2.65e-05	0.000133	CcSEcCtD
Nefazodone—Discomfort—Epirubicin—breast cancer	2.65e-05	0.000133	CcSEcCtD
Nefazodone—Asthenia—Capecitabine—breast cancer	2.64e-05	0.000133	CcSEcCtD
Nefazodone—Malaise—Doxorubicin—breast cancer	2.63e-05	0.000132	CcSEcCtD
Nefazodone—Dry mouth—Epirubicin—breast cancer	2.62e-05	0.000132	CcSEcCtD
Nefazodone—Vertigo—Doxorubicin—breast cancer	2.62e-05	0.000131	CcSEcCtD
Nefazodone—Anorexia—Methotrexate—breast cancer	2.62e-05	0.000131	CcSEcCtD
Nefazodone—Syncope—Doxorubicin—breast cancer	2.61e-05	0.000131	CcSEcCtD
Nefazodone—Pruritus—Capecitabine—breast cancer	2.61e-05	0.000131	CcSEcCtD
Nefazodone—Leukopenia—Doxorubicin—breast cancer	2.61e-05	0.000131	CcSEcCtD
Nefazodone—Diarrhoea—Docetaxel—breast cancer	2.6e-05	0.000131	CcSEcCtD
Nefazodone—Confusional state—Epirubicin—breast cancer	2.59e-05	0.00013	CcSEcCtD
Nefazodone—Palpitations—Doxorubicin—breast cancer	2.57e-05	0.000129	CcSEcCtD
Nefazodone—Oedema—Epirubicin—breast cancer	2.57e-05	0.000129	CcSEcCtD
Nefazodone—Anaphylactic shock—Epirubicin—breast cancer	2.57e-05	0.000129	CcSEcCtD
Nefazodone—Hypotension—Methotrexate—breast cancer	2.56e-05	0.000129	CcSEcCtD
Nefazodone—Loss of consciousness—Doxorubicin—breast cancer	2.56e-05	0.000129	CcSEcCtD
Nefazodone—Infection—Epirubicin—breast cancer	2.55e-05	0.000128	CcSEcCtD
Nefazodone—Cough—Doxorubicin—breast cancer	2.54e-05	0.000128	CcSEcCtD
Nefazodone—Shock—Epirubicin—breast cancer	2.53e-05	0.000127	CcSEcCtD
Nefazodone—Convulsion—Doxorubicin—breast cancer	2.52e-05	0.000127	CcSEcCtD
Nefazodone—Diarrhoea—Capecitabine—breast cancer	2.52e-05	0.000127	CcSEcCtD
Nefazodone—Dizziness—Docetaxel—breast cancer	2.52e-05	0.000127	CcSEcCtD
Nefazodone—Thrombocytopenia—Epirubicin—breast cancer	2.51e-05	0.000126	CcSEcCtD
Nefazodone—Hypertension—Doxorubicin—breast cancer	2.51e-05	0.000126	CcSEcCtD
Nefazodone—Tachycardia—Epirubicin—breast cancer	2.51e-05	0.000126	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Methotrexate—breast cancer	2.5e-05	0.000126	CcSEcCtD
Nefazodone—Hyperhidrosis—Epirubicin—breast cancer	2.48e-05	0.000125	CcSEcCtD
Nefazodone—Insomnia—Methotrexate—breast cancer	2.48e-05	0.000125	CcSEcCtD
Nefazodone—Myalgia—Doxorubicin—breast cancer	2.48e-05	0.000125	CcSEcCtD
Nefazodone—Chest pain—Doxorubicin—breast cancer	2.48e-05	0.000125	CcSEcCtD
Nefazodone—Arthralgia—Doxorubicin—breast cancer	2.48e-05	0.000125	CcSEcCtD
Nefazodone—Anxiety—Doxorubicin—breast cancer	2.47e-05	0.000124	CcSEcCtD
Nefazodone—Paraesthesia—Methotrexate—breast cancer	2.46e-05	0.000124	CcSEcCtD
Nefazodone—Discomfort—Doxorubicin—breast cancer	2.45e-05	0.000123	CcSEcCtD
Nefazodone—Anorexia—Epirubicin—breast cancer	2.45e-05	0.000123	CcSEcCtD
Nefazodone—Dyspnoea—Methotrexate—breast cancer	2.45e-05	0.000123	CcSEcCtD
Nefazodone—Somnolence—Methotrexate—breast cancer	2.44e-05	0.000123	CcSEcCtD
Nefazodone—Dizziness—Capecitabine—breast cancer	2.44e-05	0.000122	CcSEcCtD
Nefazodone—Dry mouth—Doxorubicin—breast cancer	2.42e-05	0.000122	CcSEcCtD
Nefazodone—Vomiting—Docetaxel—breast cancer	2.42e-05	0.000122	CcSEcCtD
Nefazodone—Dyspepsia—Methotrexate—breast cancer	2.42e-05	0.000121	CcSEcCtD
Nefazodone—Rash—Docetaxel—breast cancer	2.4e-05	0.000121	CcSEcCtD
Nefazodone—Hypotension—Epirubicin—breast cancer	2.4e-05	0.000121	CcSEcCtD
Nefazodone—Dermatitis—Docetaxel—breast cancer	2.4e-05	0.000121	CcSEcCtD
Nefazodone—Confusional state—Doxorubicin—breast cancer	2.4e-05	0.00012	CcSEcCtD
Nefazodone—Decreased appetite—Methotrexate—breast cancer	2.39e-05	0.00012	CcSEcCtD
Nefazodone—Headache—Docetaxel—breast cancer	2.39e-05	0.00012	CcSEcCtD
Nefazodone—Oedema—Doxorubicin—breast cancer	2.38e-05	0.000119	CcSEcCtD
Nefazodone—Anaphylactic shock—Doxorubicin—breast cancer	2.38e-05	0.000119	CcSEcCtD
Nefazodone—Infection—Doxorubicin—breast cancer	2.36e-05	0.000119	CcSEcCtD
Nefazodone—Pain—Methotrexate—breast cancer	2.35e-05	0.000118	CcSEcCtD
Nefazodone—Vomiting—Capecitabine—breast cancer	2.34e-05	0.000118	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Epirubicin—breast cancer	2.34e-05	0.000118	CcSEcCtD
Nefazodone—Shock—Doxorubicin—breast cancer	2.34e-05	0.000117	CcSEcCtD
Nefazodone—Thrombocytopenia—Doxorubicin—breast cancer	2.33e-05	0.000117	CcSEcCtD
Nefazodone—Rash—Capecitabine—breast cancer	2.32e-05	0.000117	CcSEcCtD
Nefazodone—Insomnia—Epirubicin—breast cancer	2.32e-05	0.000117	CcSEcCtD
Nefazodone—Dermatitis—Capecitabine—breast cancer	2.32e-05	0.000117	CcSEcCtD
Nefazodone—Tachycardia—Doxorubicin—breast cancer	2.32e-05	0.000117	CcSEcCtD
Nefazodone—Headache—Capecitabine—breast cancer	2.31e-05	0.000116	CcSEcCtD
Nefazodone—Paraesthesia—Epirubicin—breast cancer	2.31e-05	0.000116	CcSEcCtD
Nefazodone—Hyperhidrosis—Doxorubicin—breast cancer	2.3e-05	0.000115	CcSEcCtD
Nefazodone—Dyspnoea—Epirubicin—breast cancer	2.29e-05	0.000115	CcSEcCtD
Nefazodone—Somnolence—Epirubicin—breast cancer	2.28e-05	0.000115	CcSEcCtD
Nefazodone—Anorexia—Doxorubicin—breast cancer	2.26e-05	0.000114	CcSEcCtD
Nefazodone—Nausea—Docetaxel—breast cancer	2.26e-05	0.000114	CcSEcCtD
Nefazodone—Feeling abnormal—Methotrexate—breast cancer	2.26e-05	0.000114	CcSEcCtD
Nefazodone—Dyspepsia—Epirubicin—breast cancer	2.26e-05	0.000114	CcSEcCtD
Nefazodone—Gastrointestinal pain—Methotrexate—breast cancer	2.24e-05	0.000113	CcSEcCtD
Nefazodone—Decreased appetite—Epirubicin—breast cancer	2.23e-05	0.000112	CcSEcCtD
Nefazodone—Hypotension—Doxorubicin—breast cancer	2.22e-05	0.000112	CcSEcCtD
Nefazodone—Constipation—Epirubicin—breast cancer	2.2e-05	0.00011	CcSEcCtD
Nefazodone—Pain—Epirubicin—breast cancer	2.2e-05	0.00011	CcSEcCtD
Nefazodone—Nausea—Capecitabine—breast cancer	2.19e-05	0.00011	CcSEcCtD
Nefazodone—Urticaria—Methotrexate—breast cancer	2.18e-05	0.00011	CcSEcCtD
Nefazodone—Body temperature increased—Methotrexate—breast cancer	2.17e-05	0.000109	CcSEcCtD
Nefazodone—Abdominal pain—Methotrexate—breast cancer	2.17e-05	0.000109	CcSEcCtD
Nefazodone—Musculoskeletal discomfort—Doxorubicin—breast cancer	2.16e-05	0.000109	CcSEcCtD
Nefazodone—Insomnia—Doxorubicin—breast cancer	2.15e-05	0.000108	CcSEcCtD
Nefazodone—Paraesthesia—Doxorubicin—breast cancer	2.13e-05	0.000107	CcSEcCtD
Nefazodone—Dyspnoea—Doxorubicin—breast cancer	2.12e-05	0.000106	CcSEcCtD
Nefazodone—Feeling abnormal—Epirubicin—breast cancer	2.12e-05	0.000106	CcSEcCtD
Nefazodone—Somnolence—Doxorubicin—breast cancer	2.11e-05	0.000106	CcSEcCtD
Nefazodone—Gastrointestinal pain—Epirubicin—breast cancer	2.1e-05	0.000106	CcSEcCtD
Nefazodone—Dyspepsia—Doxorubicin—breast cancer	2.09e-05	0.000105	CcSEcCtD
Nefazodone—Decreased appetite—Doxorubicin—breast cancer	2.07e-05	0.000104	CcSEcCtD
Nefazodone—Urticaria—Epirubicin—breast cancer	2.04e-05	0.000103	CcSEcCtD
Nefazodone—Constipation—Doxorubicin—breast cancer	2.03e-05	0.000102	CcSEcCtD
Nefazodone—Pain—Doxorubicin—breast cancer	2.03e-05	0.000102	CcSEcCtD
Nefazodone—Abdominal pain—Epirubicin—breast cancer	2.03e-05	0.000102	CcSEcCtD
Nefazodone—Body temperature increased—Epirubicin—breast cancer	2.03e-05	0.000102	CcSEcCtD
Nefazodone—Hypersensitivity—Methotrexate—breast cancer	2.02e-05	0.000102	CcSEcCtD
Nefazodone—Asthenia—Methotrexate—breast cancer	1.97e-05	9.89e-05	CcSEcCtD
Nefazodone—Feeling abnormal—Doxorubicin—breast cancer	1.96e-05	9.84e-05	CcSEcCtD
Nefazodone—Gastrointestinal pain—Doxorubicin—breast cancer	1.94e-05	9.76e-05	CcSEcCtD
Nefazodone—Pruritus—Methotrexate—breast cancer	1.94e-05	9.76e-05	CcSEcCtD
Nefazodone—Hypersensitivity—Epirubicin—breast cancer	1.89e-05	9.51e-05	CcSEcCtD
Nefazodone—Urticaria—Doxorubicin—breast cancer	1.89e-05	9.49e-05	CcSEcCtD
Nefazodone—Body temperature increased—Doxorubicin—breast cancer	1.88e-05	9.44e-05	CcSEcCtD
Nefazodone—Abdominal pain—Doxorubicin—breast cancer	1.88e-05	9.44e-05	CcSEcCtD
Nefazodone—Diarrhoea—Methotrexate—breast cancer	1.88e-05	9.43e-05	CcSEcCtD
Nefazodone—Asthenia—Epirubicin—breast cancer	1.84e-05	9.26e-05	CcSEcCtD
Nefazodone—Pruritus—Epirubicin—breast cancer	1.82e-05	9.13e-05	CcSEcCtD
Nefazodone—Dizziness—Methotrexate—breast cancer	1.81e-05	9.12e-05	CcSEcCtD
Nefazodone—Diarrhoea—Epirubicin—breast cancer	1.76e-05	8.83e-05	CcSEcCtD
Nefazodone—Hypersensitivity—Doxorubicin—breast cancer	1.75e-05	8.8e-05	CcSEcCtD
Nefazodone—Vomiting—Methotrexate—breast cancer	1.74e-05	8.77e-05	CcSEcCtD
Nefazodone—Rash—Methotrexate—breast cancer	1.73e-05	8.69e-05	CcSEcCtD
Nefazodone—Dermatitis—Methotrexate—breast cancer	1.73e-05	8.69e-05	CcSEcCtD
Nefazodone—Headache—Methotrexate—breast cancer	1.72e-05	8.64e-05	CcSEcCtD
Nefazodone—Asthenia—Doxorubicin—breast cancer	1.7e-05	8.57e-05	CcSEcCtD
Nefazodone—Dizziness—Epirubicin—breast cancer	1.7e-05	8.53e-05	CcSEcCtD
Nefazodone—Pruritus—Doxorubicin—breast cancer	1.68e-05	8.45e-05	CcSEcCtD
Nefazodone—Vomiting—Epirubicin—breast cancer	1.63e-05	8.2e-05	CcSEcCtD
Nefazodone—Nausea—Methotrexate—breast cancer	1.63e-05	8.19e-05	CcSEcCtD
Nefazodone—Diarrhoea—Doxorubicin—breast cancer	1.63e-05	8.17e-05	CcSEcCtD
Nefazodone—Rash—Epirubicin—breast cancer	1.62e-05	8.14e-05	CcSEcCtD
Nefazodone—Dermatitis—Epirubicin—breast cancer	1.62e-05	8.13e-05	CcSEcCtD
Nefazodone—Headache—Epirubicin—breast cancer	1.61e-05	8.08e-05	CcSEcCtD
Nefazodone—Dizziness—Doxorubicin—breast cancer	1.57e-05	7.9e-05	CcSEcCtD
Nefazodone—Nausea—Epirubicin—breast cancer	1.53e-05	7.66e-05	CcSEcCtD
Nefazodone—Vomiting—Doxorubicin—breast cancer	1.51e-05	7.59e-05	CcSEcCtD
Nefazodone—Rash—Doxorubicin—breast cancer	1.5e-05	7.53e-05	CcSEcCtD
Nefazodone—Dermatitis—Doxorubicin—breast cancer	1.5e-05	7.52e-05	CcSEcCtD
Nefazodone—Headache—Doxorubicin—breast cancer	1.49e-05	7.48e-05	CcSEcCtD
Nefazodone—Nausea—Doxorubicin—breast cancer	1.41e-05	7.09e-05	CcSEcCtD
Nefazodone—ADRA2A—Metabolism—PTGS2—breast cancer	2.31e-06	2.81e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—CAV1—breast cancer	2.31e-06	2.81e-05	CbGpPWpGaD
Nefazodone—HTR1A—GPCR downstream signaling—AKT1—breast cancer	2.3e-06	2.81e-05	CbGpPWpGaD
Nefazodone—HTR2C—GPCR downstream signaling—AKT1—breast cancer	2.29e-06	2.79e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CASP3—breast cancer	2.28e-06	2.78e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL2—breast cancer	2.27e-06	2.78e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—SLC2A1—breast cancer	2.27e-06	2.78e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NQO1—breast cancer	2.27e-06	2.78e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—NOS3—breast cancer	2.27e-06	2.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CXCL8—breast cancer	2.27e-06	2.77e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CASP3—breast cancer	2.27e-06	2.77e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—IL6—breast cancer	2.26e-06	2.76e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL2—breast cancer	2.26e-06	2.76e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—HRAS—breast cancer	2.25e-06	2.75e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—IL6—breast cancer	2.25e-06	2.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CD—breast cancer	2.23e-06	2.73e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CCND1—breast cancer	2.22e-06	2.71e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1B—breast cancer	2.21e-06	2.7e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—JUN—breast cancer	2.21e-06	2.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—PIK3CA—breast cancer	2.21e-06	2.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SERPINE1—breast cancer	2.21e-06	2.7e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—PIK3CA—breast cancer	2.21e-06	2.69e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CCND1—breast cancer	2.21e-06	2.69e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—JUN—breast cancer	2.2e-06	2.69e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MDM2—breast cancer	2.2e-06	2.68e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CTNNB1—breast cancer	2.2e-06	2.68e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RAF1—breast cancer	2.19e-06	2.67e-05	CbGpPWpGaD
Nefazodone—ADRA1B—GPCR downstream signaling—AKT1—breast cancer	2.19e-06	2.67e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—KRAS—breast cancer	2.19e-06	2.67e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CTNNB1—breast cancer	2.18e-06	2.67e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—RELA—breast cancer	2.18e-06	2.66e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1B1—breast cancer	2.18e-06	2.66e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—CAV1—breast cancer	2.17e-06	2.65e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CASP3—breast cancer	2.17e-06	2.65e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—ERBB2—breast cancer	2.17e-06	2.65e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL2—breast cancer	2.17e-06	2.64e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—PIK3CA—breast cancer	2.16e-06	2.64e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—IL6—breast cancer	2.16e-06	2.63e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MDM2—breast cancer	2.15e-06	2.63e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MMP9—breast cancer	2.15e-06	2.63e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RAF1—breast cancer	2.15e-06	2.62e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—CDKN1A—breast cancer	2.14e-06	2.62e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MMP9—breast cancer	2.14e-06	2.61e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PTEN—breast cancer	2.14e-06	2.61e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MTOR—breast cancer	2.14e-06	2.61e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CB—breast cancer	2.14e-06	2.61e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HSP90AA1—breast cancer	2.14e-06	2.61e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—RELA—breast cancer	2.14e-06	2.61e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—CDKN1A—breast cancer	2.13e-06	2.6e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CB—breast cancer	2.13e-06	2.6e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PTEN—breast cancer	2.13e-06	2.6e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—ERBB2—breast cancer	2.12e-06	2.59e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTGS2—breast cancer	2.11e-06	2.58e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CCND1—breast cancer	2.11e-06	2.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—NOS3—breast cancer	2.11e-06	2.57e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—JUN—breast cancer	2.11e-06	2.57e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CG—breast cancer	2.1e-06	2.56e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MTOR—breast cancer	2.09e-06	2.56e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CB—breast cancer	2.09e-06	2.56e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK8—breast cancer	2.09e-06	2.55e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CTNNB1—breast cancer	2.09e-06	2.55e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling by GPCR—AKT1—breast cancer	2.09e-06	2.55e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK8—breast cancer	2.08e-06	2.54e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NCOA1—breast cancer	2.08e-06	2.54e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling by GPCR—AKT1—breast cancer	2.08e-06	2.53e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CXCL8—breast cancer	2.06e-06	2.51e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MMP9—breast cancer	2.05e-06	2.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP19A1—breast cancer	2.05e-06	2.5e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—STK11—breast cancer	2.05e-06	2.5e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—HRAS—breast cancer	2.04e-06	2.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—CDKN1A—breast cancer	2.04e-06	2.49e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PTEN—breast cancer	2.04e-06	2.49e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CXCL8—breast cancer	2.01e-06	2.46e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PTEN—breast cancer	2.01e-06	2.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—PIK3CA—breast cancer	2.01e-06	2.45e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1B—breast cancer	2.01e-06	2.45e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MDM2—breast cancer	2e-06	2.44e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—HRAS—breast cancer	2e-06	2.44e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK8—breast cancer	1.99e-06	2.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RAF1—breast cancer	1.99e-06	2.43e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling by GPCR—AKT1—breast cancer	1.99e-06	2.43e-05	CbGpPWpGaD
Nefazodone—HTR2A—GPCR downstream signaling—AKT1—breast cancer	1.99e-06	2.42e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—RELA—breast cancer	1.98e-06	2.42e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—SRC—breast cancer	1.98e-06	2.42e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CG—breast cancer	1.98e-06	2.42e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—SRC—breast cancer	1.97e-06	2.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—ERBB2—breast cancer	1.97e-06	2.41e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CASP3—breast cancer	1.97e-06	2.4e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1B—breast cancer	1.97e-06	2.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL2—breast cancer	1.96e-06	2.4e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—IL6—breast cancer	1.96e-06	2.39e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CB—breast cancer	1.95e-06	2.38e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MTOR—breast cancer	1.95e-06	2.38e-05	CbGpPWpGaD
Nefazodone—ADRA1A—GPCR downstream signaling—AKT1—breast cancer	1.94e-06	2.37e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—VEGFA—breast cancer	1.93e-06	2.36e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CASP3—breast cancer	1.93e-06	2.35e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL2—breast cancer	1.92e-06	2.35e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—VEGFA—breast cancer	1.92e-06	2.35e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CCND1—breast cancer	1.92e-06	2.34e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—IL6—breast cancer	1.91e-06	2.34e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—STAT3—breast cancer	1.91e-06	2.34e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—JUN—breast cancer	1.91e-06	2.33e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—COMT—breast cancer	1.91e-06	2.33e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—STAT3—breast cancer	1.9e-06	2.32e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CTNNB1—breast cancer	1.9e-06	2.31e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTP1—breast cancer	1.9e-06	2.31e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—SRC—breast cancer	1.89e-06	2.31e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CCND1—breast cancer	1.88e-06	2.29e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—JUN—breast cancer	1.87e-06	2.28e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—HMOX1—breast cancer	1.87e-06	2.28e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CXCL8—breast cancer	1.87e-06	2.28e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ITPR1—breast cancer	1.87e-06	2.28e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MMP9—breast cancer	1.86e-06	2.27e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—HRAS—breast cancer	1.86e-06	2.27e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CTNNB1—breast cancer	1.86e-06	2.27e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—CDKN1A—breast cancer	1.85e-06	2.26e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PTEN—breast cancer	1.85e-06	2.26e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CD—breast cancer	1.85e-06	2.25e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PTEN—breast cancer	1.84e-06	2.25e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—VEGFA—breast cancer	1.84e-06	2.25e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MAPK3—breast cancer	1.83e-06	2.23e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1B—breast cancer	1.83e-06	2.23e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—ALB—breast cancer	1.82e-06	2.22e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—STAT3—breast cancer	1.82e-06	2.22e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MMP9—breast cancer	1.82e-06	2.22e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MAPK3—breast cancer	1.82e-06	2.22e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—CDKN1A—breast cancer	1.81e-06	2.21e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PTEN—breast cancer	1.81e-06	2.21e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK8—breast cancer	1.81e-06	2.21e-05	CbGpPWpGaD
Nefazodone—ADRA2A—GPCR downstream signaling—AKT1—breast cancer	1.81e-06	2.21e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling by GPCR—AKT1—breast cancer	1.8e-06	2.2e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—PIK3CA—breast cancer	1.8e-06	2.2e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ABCB1—breast cancer	1.8e-06	2.19e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CASP3—breast cancer	1.79e-06	2.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL2—breast cancer	1.79e-06	2.18e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—IL6—breast cancer	1.78e-06	2.17e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—MYC—breast cancer	1.78e-06	2.17e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TGFB1—breast cancer	1.77e-06	2.16e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK8—breast cancer	1.77e-06	2.16e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—MYC—breast cancer	1.77e-06	2.16e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling by GPCR—AKT1—breast cancer	1.77e-06	2.16e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TGFB1—breast cancer	1.76e-06	2.15e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—TYMS—breast cancer	1.76e-06	2.15e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—NOS3—breast cancer	1.74e-06	2.13e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PLA2G4A—breast cancer	1.74e-06	2.13e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GSTM1—breast cancer	1.74e-06	2.13e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NCOR1—breast cancer	1.74e-06	2.13e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CCND1—breast cancer	1.74e-06	2.13e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MAPK3—breast cancer	1.74e-06	2.12e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CD—breast cancer	1.74e-06	2.12e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—EGFR—breast cancer	1.74e-06	2.12e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—JUN—breast cancer	1.74e-06	2.12e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—EGFR—breast cancer	1.73e-06	2.11e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CTNNB1—breast cancer	1.73e-06	2.11e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—ALB—breast cancer	1.72e-06	2.1e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—SRC—breast cancer	1.71e-06	2.09e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—MYC—breast cancer	1.69e-06	2.07e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MMP9—breast cancer	1.69e-06	2.06e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TGFB1—breast cancer	1.69e-06	2.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—CDKN1A—breast cancer	1.69e-06	2.06e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PTEN—breast cancer	1.68e-06	2.05e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—SRC—breast cancer	1.68e-06	2.05e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—VEGFA—breast cancer	1.67e-06	2.04e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—GPX1—breast cancer	1.67e-06	2.04e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—EGFR—breast cancer	1.66e-06	2.02e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—STAT3—breast cancer	1.65e-06	2.02e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CYP1A1—breast cancer	1.65e-06	2.02e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK8—breast cancer	1.65e-06	2.01e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—NOS3—breast cancer	1.64e-06	2.01e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—KRAS—breast cancer	1.64e-06	2.01e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling by GPCR—AKT1—breast cancer	1.64e-06	2e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ERCC2—breast cancer	1.64e-06	2e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—VEGFA—breast cancer	1.64e-06	2e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—KRAS—breast cancer	1.63e-06	1.99e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—STAT3—breast cancer	1.62e-06	1.98e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CB—breast cancer	1.61e-06	1.96e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTGS2—breast cancer	1.59e-06	1.95e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MAPK3—breast cancer	1.58e-06	1.93e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—KRAS—breast cancer	1.56e-06	1.91e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—SRC—breast cancer	1.56e-06	1.9e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MAPK3—breast cancer	1.55e-06	1.89e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—MTHFR—breast cancer	1.54e-06	1.88e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—MYC—breast cancer	1.54e-06	1.87e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TGFB1—breast cancer	1.53e-06	1.87e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—VEGFA—breast cancer	1.52e-06	1.85e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CB—breast cancer	1.52e-06	1.85e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—PIK3CA—breast cancer	1.51e-06	1.84e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—MYC—breast cancer	1.5e-06	1.84e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—STAT3—breast cancer	1.5e-06	1.84e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTGS2—breast cancer	1.5e-06	1.83e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—EGFR—breast cancer	1.5e-06	1.83e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—PIK3CA—breast cancer	1.5e-06	1.83e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TGFB1—breast cancer	1.5e-06	1.83e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—EGFR—breast cancer	1.47e-06	1.8e-05	CbGpPWpGaD
Nefazodone—CYP3A7—Metabolism—AKT1—breast cancer	1.47e-06	1.79e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—TP53—breast cancer	1.46e-06	1.78e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—TP53—breast cancer	1.45e-06	1.77e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—PIK3CA—breast cancer	1.44e-06	1.75e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MAPK3—breast cancer	1.44e-06	1.75e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—CAV1—breast cancer	1.42e-06	1.73e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—KRAS—breast cancer	1.42e-06	1.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—PIK3CA—breast cancer	1.42e-06	1.73e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—MYC—breast cancer	1.4e-06	1.71e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—HRAS—breast cancer	1.4e-06	1.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TGFB1—breast cancer	1.39e-06	1.7e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PTEN—breast cancer	1.39e-06	1.7e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—TP53—breast cancer	1.39e-06	1.7e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—KRAS—breast cancer	1.39e-06	1.7e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—HRAS—breast cancer	1.39e-06	1.7e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—EGFR—breast cancer	1.37e-06	1.67e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—IL6—breast cancer	1.34e-06	1.63e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—HRAS—breast cancer	1.33e-06	1.62e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—IL6—breast cancer	1.33e-06	1.62e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PTEN—breast cancer	1.31e-06	1.6e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—PIK3CA—breast cancer	1.3e-06	1.59e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—PIK3CA—breast cancer	1.3e-06	1.59e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CG—breast cancer	1.29e-06	1.58e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—KRAS—breast cancer	1.29e-06	1.58e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—PIK3CA—breast cancer	1.28e-06	1.56e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—IL6—breast cancer	1.27e-06	1.55e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—TP53—breast cancer	1.26e-06	1.54e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—TP53—breast cancer	1.24e-06	1.51e-05	CbGpPWpGaD
Nefazodone—HTR1A—Signaling Pathways—AKT1—breast cancer	1.23e-06	1.51e-05	CbGpPWpGaD
Nefazodone—HTR2C—Signaling Pathways—AKT1—breast cancer	1.23e-06	1.5e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—HRAS—breast cancer	1.21e-06	1.47e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—PIK3CA—breast cancer	1.19e-06	1.45e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—HRAS—breast cancer	1.18e-06	1.44e-05	CbGpPWpGaD
Nefazodone—ADRA1B—Signaling Pathways—AKT1—breast cancer	1.17e-06	1.43e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Metabolism—AKT1—breast cancer	1.16e-06	1.41e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—IL6—breast cancer	1.15e-06	1.41e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—TP53—breast cancer	1.15e-06	1.4e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CD—breast cancer	1.14e-06	1.39e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—IL6—breast cancer	1.13e-06	1.38e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—ALB—breast cancer	1.12e-06	1.37e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—HRAS—breast cancer	1.1e-06	1.34e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—NOS3—breast cancer	1.07e-06	1.31e-05	CbGpPWpGaD
Nefazodone—HTR2A—Signaling Pathways—AKT1—breast cancer	1.07e-06	1.3e-05	CbGpPWpGaD
Nefazodone—CYP3A5—Metabolism—AKT1—breast cancer	1.06e-06	1.3e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—IL6—breast cancer	1.05e-06	1.28e-05	CbGpPWpGaD
Nefazodone—ADRA1A—Signaling Pathways—AKT1—breast cancer	1.04e-06	1.27e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CB—breast cancer	9.92e-07	1.21e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTGS2—breast cancer	9.83e-07	1.2e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—PIK3CA—breast cancer	9.81e-07	1.2e-05	CbGpPWpGaD
Nefazodone—ADRA2A—Signaling Pathways—AKT1—breast cancer	9.69e-07	1.18e-05	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—PIK3CA—breast cancer	9.25e-07	1.13e-05	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PTEN—breast cancer	8.57e-07	1.05e-05	CbGpPWpGaD
Nefazodone—ABCB1—Metabolism—AKT1—breast cancer	8.02e-07	9.78e-06	CbGpPWpGaD
Nefazodone—CYP2D6—Metabolism—AKT1—breast cancer	7.55e-07	9.22e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—PIK3CA—breast cancer	6.05e-07	7.38e-06	CbGpPWpGaD
Nefazodone—CYP3A4—Metabolism—AKT1—breast cancer	4.94e-07	6.03e-06	CbGpPWpGaD
